ID   C80
AC   CVCL_5249
DR   cancercelllines; CVCL_5249
DR   CancerTools; 151759
DR   Cell_Model_Passport; SIDM01549
DR   ColonAtlas; C80
DR   Cosmic; 948830
DR   Cosmic; 986010
DR   Cosmic; 995390
DR   Cosmic; 1043802
DR   Cosmic; 1223132
DR   Cosmic; 1312294
DR   Cosmic; 1479604
DR   Cosmic; 2301961
DR   Cosmic; 2760096
DR   DepMap; ACH-001459
DR   ECACC; 12022904
DR   GEO; GSM1346863
DR   GEO; GSM1374423
DR   GEO; GSM1448202
DR   GEO; GSM3145696
DR   IARC_TP53; 21747
DR   PRIDE; PXD005354
DR   PRIDE; PXD005355
DR   Wikidata; Q54808248
DR   Ximbio; 151759
RX   PubMed=8464898;
RX   PubMed=10051639;
RX   PubMed=10737795;
RX   PubMed=16418264;
RX   PubMed=18258742;
RX   PubMed=20570890;
RX   PubMed=20606684;
RX   PubMed=23272949;
RX   PubMed=24755471;
RX   PubMed=25926053;
RX   PubMed=29101300;
CC   Part of: AstraZeneca Colorectal cell line (AZCL) panel.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   HLA typing: A*03 (PubMed=8464898).
CC   Microsatellite instability: Stable (MSS) (PubMed=24755471; PubMed=25926053).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Leu629Ter (c.1886T>G); ClinVar=VCV000429049; Zygosity=Unspecified (PubMed=24755471).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala146Val (c.437C>T); ClinVar=VCV000375962; Zygosity=Unspecified (PubMed=20570890; DepMap).
CC   Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp351His (c.1051G>C); ClinVar=VCV000375998; Zygosity=Unspecified (PubMed=24755471).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln52Ter (c.154C>T); ClinVar=VCV001455400; Zygosity=Unspecified (PubMed=16418264).
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Rectum; UBERON=UBERON_0001052.
ST   Source(s): DepMap; ECACC; PubMed=25926053
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 8,11
ST   D16S539: 9,10
ST   D18S51: 18
ST   D21S11: 28,29
ST   D3S1358: 16,17
ST   D5S818: 11,12
ST   D7S820: 10,11
ST   D8S1179: 13,14
ST   FGA: 20,21
ST   Penta D: 12,16
ST   Penta E: 18
ST   TH01: 6,7
ST   TPOX: 8,12
ST   vWA: 14,18
DI   NCIt; C9383; Rectal adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   69Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 29
//
RX   PubMed=8464898; DOI=10.1073/pnas.90.7.2842;
RA   Browning M.J., Krausa P., Rowan A.J., Bicknell D.C., Bodmer J.G.,
RA   Bodmer W.F.;
RT   "Tissue typing the HLA-A locus from genomic DNA by sequence-specific
RT   PCR: comparison of HLA genotype and surface expression on colorectal
RT   tumor cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:2842-2845(1993).
//
RX   PubMed=10051639; DOI=10.1073/pnas.96.5.2316;
RA   Efstathiou J.A., Liu D., Wheeler J.M., Kim H.C., Beck N.E., Ilyas M.,
RA   Karayiannakis A.J., Mortensen N.J., Kmiot W., Playford R.J.,
RA   Pignatelli M., Bodmer W.F.;
RT   "Mutated epithelial cadherin is associated with increased
RT   tumorigenicity and loss of adhesion and of responsiveness to the
RT   motogenic trefoil factor 2 in colon carcinoma cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:2316-2321(1999).
//
RX   PubMed=10737795; DOI=10.1073/pnas.97.7.3352;
RA   Rowan A.J., Lamlum H., Ilyas M., Wheeler J., Straub J.,
RA   Papadopoulou A., Bicknell D.C., Bodmer W.F., Tomlinson I.P.M.;
RT   "APC mutations in sporadic colorectal tumors: a mutational 'hotspot'
RT   and interdependence of the 'two hits'.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:3352-3357(2000).
//
RX   PubMed=16418264; DOI=10.1073/pnas.0510146103;
RA   Liu Y., Bodmer W.F.;
RT   "Analysis of P53 mutations and their expression in 56 colorectal
RT   cancer cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:976-981(2006).
//
RX   PubMed=18258742; DOI=10.1073/pnas.0712176105;
RA   Emaduddin M., Bicknell D.C., Bodmer W.F., Feller S.M.;
RT   "Cell growth, global phosphotyrosine elevation, and c-Met
RT   phosphorylation through Src family kinases in colorectal cancer
RT   cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:2358-2362(2008).
//
RX   PubMed=20570890; DOI=10.1158/0008-5472.CAN-10-0192;
RA   Janakiraman M., Vakiani E., Zeng Z.-S., Pratilas C.A., Taylor B.S.,
RA   Chitale D., Halilovic E., Wilson M., Huberman K., Ricarte Filho J.C.M.,
RA   Persaud Y., Levine D.A., Fagin J.A., Jhanwar S.C., Mariadason J.M.,
RA   Lash A., Ladanyi M., Saltz L.B., Heguy A., Paty P.B., Solit D.B.;
RT   "Genomic and biological characterization of exon 4 KRAS mutations in
RT   human cancer.";
RL   Cancer Res. 70:5901-5911(2010).
//
RX   PubMed=20606684; DOI=10.1038/sj.bjc.6605780;
RA   Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.;
RT   "5-fluorouracil response in a large panel of colorectal cancer cell
RT   lines is associated with mismatch repair deficiency.";
RL   Br. J. Cancer 103:340-346(2010).
//
RX   PubMed=23272949; DOI=10.1186/1755-8794-5-66;
RA   Schlicker A., Beran G., Chresta C.M., McWalter G., Pritchard A.,
RA   Weston S., Runswick S., Davenport S., Heathcote K., Castro D.A.,
RA   Orphanides G., French T., Wessels L.F.A.;
RT   "Subtypes of primary colorectal tumors correlate with response to
RT   targeted treatment in colorectal cell lines.";
RL   BMC Med. Genomics 5:66.1-66.15(2012).
//
RX   PubMed=24755471; DOI=10.1158/0008-5472.CAN-14-0013;
RA   Mouradov D., Sloggett C., Jorissen R.N., Love C.G., Li S.,
RA   Burgess A.W., Arango D., Strausberg R.L., Buchanan D., Wormald S.,
RA   O'Connor L., Wilding J.L., Bicknell D.C., Tomlinson I.P.M., Bodmer W.F.,
RA   Mariadason J.M., Sieber O.M.;
RT   "Colorectal cancer cell lines are representative models of the main
RT   molecular subtypes of primary cancer.";
RL   Cancer Res. 74:3238-3247(2014).
//
RX   PubMed=25926053; DOI=10.1038/ncomms8002;
RA   Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G.,
RA   Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S.,
RA   Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M.,
RA   Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.;
RT   "The molecular landscape of colorectal cancer cell lines unveils
RT   clinically actionable kinase targets.";
RL   Nat. Commun. 6:7002.1-7002.10(2015).
//
RX   PubMed=29101300; DOI=10.15252/msb.20177701;
RA   Frejno M., Zenezini Chiozzi R., Wilhelm M., Koch H., Zheng R.-S.,
RA   Klaeger S., Ruprecht B., Meng C., Kramer K., Jarzab A., Heinzlmeir S.,
RA   Johnstone E., Domingo E., Kerr D., Jesinghaus M., Slotta-Huspenina J.,
RA   Weichert W., Knapp S., Feller S.M., Kuster B.;
RT   "Pharmacoproteomic characterisation of human colon and rectal
RT   cancer.";
RL   Mol. Syst. Biol. 13:951-951(2017).
//